

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part Series

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Data from the Phase III AMPLIFY trial reported a statistically significant improvement in progression-free survival with which Bruton tyrosine kinase (BTK) inhibitor combined with venetoclax, with or without obinutuzumab, in comparison to chemoimmunotherapy for patients with untreated chronic lymphocytic leukemia (CLL)?**
 - Fixed-duration ibrutinib
 - Fixed-duration pirtobrutinib
 - Fixed-duration acalabrutinib
 - Fixed-duration zanubrutinib
- Which of the following outcomes was reported from an analysis of the safety and tolerability of pirtobrutinib monotherapy specifically for patients enrolled in the BRUIN trial with relapsed/refractory B-cell cancers who had experienced intolerance to a prior covalent BTK inhibitor?**
 - Most patients who had discontinued a BTK inhibitor because of a treatment-emergent adverse event (TEAE) discontinued pirtobrutinib for the same TEAE
 - Approximately 20% of patients who had discontinued a BTK inhibitor because of a TEAE discontinued pirtobrutinib for the same TEAE
 - No patient who had discontinued a BTK inhibitor because of a TEAE discontinued pirtobrutinib for the same TEAE
- A report assessing the risk of bleeding for patients with B-cell cancers in the BRUIN study who received pirtobrutinib monotherapy with or without concomitant antithrombotic therapy (AT) revealed which of the following observations in the AT-exposed group?**
 - The majority of these patients experienced a bleeding/bruising event leading to dose reduction of pirtobrutinib
 - Approximately 15% of these patients experienced a bleeding/bruising event leading to dose reduction of pirtobrutinib
 - None of these patients experienced a bleeding/bruising event leading to dose reduction of pirtobrutinib
- An analysis of the activity of pirtobrutinib in the subgroup of patients with Richter's transformation enrolled in the BRUIN trial demonstrated which of the following?**
 - Half of the patients achieved a clinical response, but no complete responses were observed
 - Half of the patients achieved a clinical response, and several complete responses were observed
 - A small minority of patients achieved a clinical response
- The EPCORE CLL-1 trial of epcoritamab demonstrated activity in which group of patients with relapsed or refractory CLL?**
 - The overall patient population, but not patients harboring a TP53 aberration
 - Only patients harboring a TP53 aberration
 - The overall population and patients harboring a TP53 aberration